NASDAQ:HALO Halozyme Therapeutics (HALO) Stock Forecast, Price & News $32.43 -0.42 (-1.28%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$32.41▼$33.3950-Day Range$30.28▼$38.7452-Week Range$29.85▼$59.46Volume935,619 shsAverage Volume1.21 million shsMarket Capitalization$4.27 billionP/E Ratio24.76Dividend YieldN/APrice Target$54.78 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Halozyme Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside68.9% Upside$54.78 Price TargetShort InterestBearish5.05% of Float Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment1.15Based on 11 Articles This WeekInsider TradingSelling Shares$1.72 M Sold Last QuarterProj. Earnings Growth44.86%From $2.43 to $3.52 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.32 out of 5 starsMedical Sector3rd out of 1,006 stocksBiological Products, Except Diagnostic Industry1st out of 167 stocks 4.4 Analyst's Opinion Consensus RatingHalozyme Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $54.78, Halozyme Therapeutics has a forecasted upside of 68.9% from its current price of $32.43.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.05% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Halozyme Therapeutics has recently increased by 2.33%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHalozyme Therapeutics has received a 65.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Biopharmaceuticals" and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Halozyme Therapeutics is -1.12. Previous Next 3.4 News and Social Media Coverage News SentimentHalozyme Therapeutics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Halozyme Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.MarketBeat Follows5 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,719,100.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions96.32% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 44.86% in the coming year, from $2.43 to $3.52 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 24.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.60.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 24.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.58.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.53. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 64.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Halozyme Therapeutics (NASDAQ:HALO) StockHalozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.Read More Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Stock News HeadlinesMay 29, 2023 | americanbankingnews.comBrokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $55.30May 26, 2023 | americanbankingnews.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) to Post Q2 2023 Earnings of $0.54 Per Share, Zacks Research ForecastsJune 1, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 26, 2023 | americanbankingnews.comHead-To-Head Review: Ginkgo Bioworks (NYSE:DNA) & Halozyme Therapeutics (NASDAQ:HALO)May 22, 2023 | msn.comUnusual Put Option Trade in Halozyme Therapeutics (HALO) Worth $170.30KMay 22, 2023 | finance.yahoo.comHere’s Why Halozyme Therapeutics (HALO) Declined in Q1May 16, 2023 | finance.yahoo.comHalozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 63% Above Its Share PriceMay 12, 2023 | msn.comJMP Securities Reiterates Halozyme Therapeutics (HALO) Market Outperform RecommendationJune 1, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 12, 2023 | msn.comPiper Sandler Upgrades Halozyme Therapeutics (HALO)May 11, 2023 | msn.comMorgan Stanley Maintains Halozyme Therapeutics (HALO) Overweight RecommendationMay 11, 2023 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Updates FY23 Earnings GuidanceMay 11, 2023 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Upgraded to "Overweight" by Piper SandlerMay 10, 2023 | finance.yahoo.comHalozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/YMay 10, 2023 | markets.businessinsider.comPositive Report for Halozyme (HALO) from Piper SandlerMay 10, 2023 | finance.yahoo.com4 big analyst picks: Alcon upgraded to Outperform after Q1 beat | Pro RecapMay 10, 2023 | markets.businessinsider.comGoldman Sachs Reaffirms Their Buy Rating on Halozyme (HALO)May 9, 2023 | yahoo.comHALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTSMay 9, 2023 | msn.comHalozyme Therapeutics: Q1 Earnings InsightsMay 8, 2023 | msn.comHalozyme Therapeutics Earnings PreviewMay 8, 2023 | markets.businessinsider.comHere's what Wall Street expects from Halozyme Therapeutics's earningsMay 8, 2023 | americanbankingnews.comHalozyme Therapeutics (HALO) to Release Earnings on TuesdayMay 4, 2023 | americanbankingnews.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesApril 26, 2023 | finance.yahoo.comHalozyme Therapeutics, Inc. (HALO)April 25, 2023 | finance.yahoo.comHalozyme To Report First Quarter 2023 Financial and Operating ResultsApril 25, 2023 | finance.yahoo.comHalozyme Therapeutics (HALO) Declined on 2023 Profit OutlookApril 25, 2023 | americanbankingnews.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Forecasted to Post Q2 2023 Earnings of $0.57 Per ShareSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HALO Company Calendar Last Earnings11/02/2021Today5/31/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:HALO CUSIP40637H10 CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees145Year Founded1998Price Target and Rating Average Stock Price Forecast$54.78 High Stock Price Forecast$68.00 Low Stock Price Forecast$42.00 Forecasted Upside/Downside+68.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$1.31 Trailing P/E Ratio24.76 Forward P/E Ratio13.35 P/E Growth0.53Net Income$202.13 million Net Margins25.76% Pretax Margin32.16% Return on Equity184.32% Return on Assets16.05% Debt Debt-to-Equity Ratio22.69 Current Ratio6.69 Quick Ratio5.52 Sales & Book Value Annual Sales$660.12 million Price / Sales6.47 Cash Flow$2.53 per share Price / Cash Flow12.80 Book Value$0.50 per share Price / Book64.86Miscellaneous Outstanding Shares131,680,000Free Float128,651,000Market Cap$4.27 billion OptionableOptionable Beta1.21 Social Links Key ExecutivesDr. Helen I. Torley M.B. Ch. B. (Age 59)M.R.C.P., Pres, CEO & Director Comp: $1.65MDr. Michael J. LaBarre Ph.D. (Age 58)Chief Technical Officer Comp: $779.55kMs. Nicole LaBrosse (Age 39)CFO & Director Ms. Tram BuiVP of Investor Relations & Corp. CommunicationsMr. Mark Snyder Esq.Gen. Counsel, Chief Compliance Officer & Corp. Sec.Ms. Amy Marinne FoxChief HR OfficerDr. Steve Knowles MBBSChief Medical OfficerMr. Todd ButlerChief of Staff to the CEO, VP & Head of Project ManagementDr. Christopher Bryant Ph.D. (Age 61)Chief Manufacturing Officer & Head of Technical Operations More ExecutivesKey CompetitorsExelixisNASDAQ:EXELBioCryst PharmaceuticalsNASDAQ:BCRXNeurocrine BiosciencesNASDAQ:NBIXRepligenNASDAQ:RGENVaxcyteNASDAQ:PCVXView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 5,596 shares on 5/26/2023Ownership: 0.025%Empower Advisory Group LLCBought 7,387 shares on 5/25/2023Ownership: 0.006%Verity Asset Management Inc.Bought 4,778 shares on 5/24/2023Ownership: 0.024%Royce & Associates LPSold 51,000 shares on 5/23/2023Ownership: 0.034%International Biotechnology Trust PLCBought 45,500 shares on 5/18/2023Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions HALO Stock - Frequently Asked Questions Should I buy or sell Halozyme Therapeutics stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HALO shares. View HALO analyst ratings or view top-rated stocks. What is Halozyme Therapeutics' stock price forecast for 2023? 9 Wall Street research analysts have issued 12 month price targets for Halozyme Therapeutics' shares. Their HALO share price forecasts range from $42.00 to $68.00. On average, they expect the company's stock price to reach $54.78 in the next twelve months. This suggests a possible upside of 68.9% from the stock's current price. View analysts price targets for HALO or view top-rated stocks among Wall Street analysts. How have HALO shares performed in 2023? Halozyme Therapeutics' stock was trading at $56.90 at the start of the year. Since then, HALO shares have decreased by 43.0% and is now trading at $32.43. View the best growth stocks for 2023 here. When is Halozyme Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our HALO earnings forecast. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings data on Tuesday, November, 2nd. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $0.42 by $1.06. The biopharmaceutical company earned $115.83 million during the quarter, compared to analyst estimates of $101.94 million. Halozyme Therapeutics had a net margin of 25.76% and a trailing twelve-month return on equity of 184.32%. During the same quarter in the previous year, the business earned $0.25 EPS. What ETFs hold Halozyme Therapeutics' stock? ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include Future Fund Active ETF (FFND), Invesco Dynamic Biotechnology & Genome ETF (PBE), Goldman Sachs Future Health Care Equity ETF (GDOC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Invesco S&P MidCap 400 Pure Growth ETF (RFG), BlackRock Future Innovators ETF (BFTR) and Invesco Russell 2000 Dynamic Multifactor ETF (OMFS). What guidance has Halozyme Therapeutics issued on next quarter's earnings? Halozyme Therapeutics updated its FY23 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of $2.50-$2.65 for the period, compared to the consensus estimate of $2.58. The company issued revenue guidance of $815-$845 million, compared to the consensus revenue estimate of $832.97 million. What is Helen Torley's approval rating as Halozyme Therapeutics' CEO? 12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV). What is Halozyme Therapeutics' stock symbol? Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO." Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Artisan Partners Limited Partnership (5.16%), Snyder Capital Management L P (3.26%), Macquarie Group Ltd. (2.43%), Geode Capital Management LLC (2.00%), GW&K Investment Management LLC (1.77%) and Charles Schwab Investment Management Inc. (1.25%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Halozyme Therapeutics' stock price today? One share of HALO stock can currently be purchased for approximately $32.43. How much money does Halozyme Therapeutics make? Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $4.27 billion and generates $660.12 million in revenue each year. The biopharmaceutical company earns $202.13 million in net income (profit) each year or $1.31 on an earnings per share basis. How many employees does Halozyme Therapeutics have? The company employs 145 workers across the globe. Does Halozyme Therapeutics have any subsidiaries? The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.Read More How can I contact Halozyme Therapeutics? Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311. This page (NASDAQ:HALO) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.